Therapeutic Class

ORBAX® Oral Suspension

Pharmaceutical Name

Orbax-Detailer-Cover.ORBAX® Oral Suspension
The once-a-day antibiotic cats actually like.
Bound to a taste-masking agent, orbifloxacin passes taste buds undetected.
Cats taste the malt flavor, not the antibiotic.


New! Taste-Masking Technology

  • Orbifloxacin is bound to a patented taste-masking agent so it passes taste buds undetected, then is released in the low pH environment of the stomach. Cats and dogs taste the malt flavor, not the antibiotic.
  • In a clinical trial with ill cats, ORBAX®Oral Suspension was readily accepted by 95% of cats, while only 54% of cats readily accepted Synulox® (European tradename of Clavamox® Drops).1
  • In a clinical trial with client‑owned dogs, ORBAX® Oral Suspension was accepted by 96% of dogs presented for veterinary care.2
Convenient for pet owners

  • Administered once-a-day
  • Unique press-in dispensing system (3 mL syringe with 0.25 mL markings)
    - Makes dosing easy and accurate, administration mess-free
  • No refrigeration needed
  • Ready to use, no need to reconstitute, simply shake well

  • Skin infections (wounds and abscesses) in cats*3
  • Skin and soft tissue infections (wounds and abscesses) and urinary tract infections (cystitis) in dogs*4

*Caused by susceptible strains of bacteria as listed in approved indications.
Please see the Package Insert for full prescribing information.

Fair Balance

Quinolones have been shown to cause arthropathy in immature animals. In animals with known or suspected CNS disorders, quinolones have been associated with CNS stimulation, which may lead to convulsive seizures.

The use of fluoroquinolones in cats has been reported to adversely affect the retina and should be used with caution in cats.


  1. Data on file. Multi-clinic, randomized, controlled field trail evaluating the use of ORBAX® (orbifloxacin) Oral Suspension and Synulox® (amoxicillin/clavulanate) in the treatment of cats with skin and soft tissue infections (primarily post-traumatic wounds and absesses) in France, Belgium, and Germany in 2001. Roseland, NJ: Intervet Inc.
  2. Freedom of Information Summary. Original New Animal Drug Application (NADA 141-305). ORBAX® Oral Suspension. Roseland, NJ: Intervet Inc. July 1, 2009
  3. Prescribing information for ORBAX® Oral Suspension for Oral Use in Cats. Summit, NJ: Intervet Inc. 2011.
  4. Prescribing information for ORBAX® Oral Suspension for Oral Use in Dogs. Summit, NJ: Intervet Inc. 2011.

Copyright © 2012, Intervet Inc., a subsidiary of Merck & Co., Inc. All rights reserved. Intervet Inc. d/b/a Merck Animal Health, Summit, NJ 07901.

Product Label(s) and MSDS